Net price increases for seven drugs raised U.S. drug spending by $5.1 billion between 2017 and 2018 without evidence of improved safety or effectiveness, according to the first annual report by the Institute for Clinical and Economic Review on the costliest U.S. drug price increases unsupported by clinical evidence. For example, the average U.S. price for Humira, a drug used to treat chronic illnesses such as rheumatoid arthritis, increased 15.9% over the period after accounting for rebates and other concessions, raising spending on the drug by an additional $1.86 billion. “If new evidence emerges that shows a treatment may be more beneficial than what was previously understood, perhaps that new evidence could warrant some level of price increase,” said David Rind, M.D., chief medical officer for the independent research institute. “For seven of the nine drugs we reviewed, however, we found that the price increases lacked justification in new evidence.”

Related News Articles

Headline
The Senate Finance Committee held on Tuesday the third in a series of hearings on drug pricing in America, which focused on the role of pharmacy benefit…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held the
Headline
A Department of Health and Human Services’ Office of Inspector General proposal to change drug discount safe harbors under the federal anti-kickback statute…
Headline
The House Committee on Energy and Commerce yesterday passed a number of AHA-supported bills that would lower prescription drug costs and strengthen the…
Headline
The AHA expressed support for a number of bills being considered today by the House Committee on Energy and Commerce that would lower prescription drug costs…
Headline
The House Energy and Commerce Health Subcommittee today approved five